Impact of F2R polymorphisms on clopidogrel treatment outcomes in acute stroke

Takeaway

  • Clopidogrel, a P2Y12 inhibitor, combined with aspirin in the treatment of acute stroke and transient ischemic attack (TIA) is associated with a reduced risk of stroke in individuals carrying a T allele in the protease-activated receptors-1 (PAR-1) gene F2R polymorphism, F2R IVSn -14.

Why this matters

    Through genetic testing, physicians may be able to distinguish individuals who will benefit from combined clopidogrel and aspirin therapy, following acute ischemic stroke or TIA.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.